MicroPort Scientific Corporation
MicroPort - Model Firehawk - Rapamycin Target Eluting Coronary Stent System
TARGET All Comers Trial: 1,656 Patients from 20 sites in Europe. 1:1 RCT Real World open-label, non-inferiority trial
Primary endpoint: TLF @12 months. Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe. and effective across a broad spectrum of patient and lesion complexity.
Most popular related searches
drug eluting stent
eluting stent
percutaneous coronary intervention
stent thrombosis
drug eluting
stent material
coronary interventional
coronary intervention
stent system
coronary stent
The result is a unique solution that combines the strength of both drug eluting stents and bare metal stents.
With the continuous increase in the body of clinical evidence to demonstrate its `golden standard` in safety and efficacy, Firehawk® is establishing its status as an elite workhorse drug-eluting stent for clinics across the globe.
CLINICAL EVIDENCE
PROB/DEFINITE STENT THROMBOSIS AT 1 YEAR
- 1-year Stent thrombosis rate result shows non-inferiority than Durable-Polymer DES
- Shows proven safety in all comers population
- Stent Material: L605 CoCr
- Polymer: PLA, 100% Biodegradable
- Drug: Rapamycin (Sirolimus)
- Drug Dosage: 0.3 µg/mm2
- Strut Thickness:
- 86µm (Ø2.25mm - 3.0mm)
- 96.5µm (Ø3.5mm - 4.0mm)
- Nomial Pressure: 10 atm
- Rated Burst Pressure:
- 16 atm (Ø2.25mm - 3.5mm)
- 14 atm (Ø4.0mm)
- Mean Recoil: 3.4%
- Mean Foreshortening: 1.95% - 5.30%
